


Patent Docket P1150R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ashkenazi et al.	Examiner: L. Sun-Hoffman
Serial No.: 09/195,368	Art Unit: 1642
Filed: November 18, 1998	CERTIFICATE OF MAILING
For: DNA19355, A Tumor Necrosis Factor Homolog	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on March 7, 2000  Tara E. Faenza

#8/B
LO
323-10

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION
CONTAINING SEQUENCE DISCLOSURES;
RESPONSE TO RESTRICTION REQUIREMENT; AND
PRELIMINARY AMENDMENT**

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This paper is being filed in response to the Office communication mailed December 7, 1999. Entry of the following amendment is requested prior to examination on the merits.

MAR 17 2000
TECH CENTER 1600/2900

IN THE SPECIFICATION:

Please enter into the specification the attached substitute paper copy of the Sequence Listing which includes 5 pages and provides sequences identified as SEQ ID NOS: 1-8.

IN THE CLAIMS:

Please cancel claims 10-26 without prejudice.

REMARKS

Claims 1-26 are pending and are the subject of the office action.

In the office action, the Examiner set forth a restriction requirement pursuant to 35 USC Section 121. Specifically, the Examiner set forth a restriction of five (5) groups of claims, Groups I - V. Applicants hereby elect to prosecute in the instant